期刊文献+

应用组织芯片技术检测核仁组成区相关蛋白对乳腺导管不典型增生和导管原位癌的诊断意义 被引量:2

Significance of the diagnosis of AgNOR analysis in atypical ductal hyperplasia and ductal carcinomain situ of the breast by the application of tissue mi croarray technology
暂未订购
导出
摘要 目的 探讨核仁组成区相关蛋白 (AgNOR)对乳腺导管不典型增生 (ADH)和导管原位癌 (DCIS)的诊断意义。方法 应用组织芯片技术对 2 0例乳腺不典型增生和 2 0例乳腺导管原位癌的AgNOR进行图象定量分析 ,获得四个参数 ,包括 :每个细胞AgNOR颗粒平均个数、AgNOR颗粒总面积、单个颗粒AgNOR平均面积、AgNOR面积 核面积。结果 每个细胞AgNOR颗粒平均个数、AgNOR颗粒总面积两个参数ADH和DCIS的差异有统计学意义 (P =0 0 0 0 ,P =0 0 0 1) ,DCIS明显高于ADH。这两个参数ADH和低度DCIS的差异也有统计学意义 (P =0 0 0 0 ,P =0 0 0 3 )。结论 AgNOR图象定量分析结果可以作为辅助诊断ADH和DCIS的指标。组织芯片技术有良好的应用价值和广阔的应用前景。 Objective To explore the diagn ostic significance of argyrophilic nucleolar organizer regions ( AgNORs) in atyp ical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) of the breast . Methods Image analysis of AgNOR i n tissue microarray sections from biopsies of 20 breast ADH and 20 breast DCIS w as by the application of tissue microarray technology.Four parameters were acqu ire d,including the number of AgNORs per nucleus,total area of AgNORs,mean area o f a single AgNOR and the ratio AgNOR sum area/nuclear area. Results AgNOR number and total AgNOR are a increased from ADH to DCIS,and the differences between A DH and DCIS(low grade) were statistically significant.The other tw o parameters also increased from ADH to DCIS,but the differences were not stati stically significant. Conclusion AgNOR may be regarded as an assistant index of the diagnosis of ADH and DCIS.Tissue micr oarray technology has important practical significance and broad application pro spect in pathology.
作者 刘晖 张长淮
出处 《临床和实验医学杂志》 2004年第1期3-5,共3页 Journal of Clinical and Experimental Medicine
关键词 乳腺肿瘤 核仁组成区相关蛋白 不典型增生 原位癌 图像分析 组织芯片 Breast neoplasia Argyrophilic n u cleolar organizer regions Atypical ductal hyperplasia Ductal carcinoma in situ Image analysis Tissue microarray
  • 相关文献

参考文献4

二级参考文献18

  • 1余景瑞,孙幼芳.核仁组成区测定对胃癌和癌前病变诊断上的意义[J].癌症,1993,12(1):30-32. 被引量:7
  • 2王戈华.核仁组织者区银染色与恶性肿瘤细胞核糖体核酸基因转录活性的关系[J].国外医学肿瘤分册,1983,2:82-82.
  • 3许良中.关于组成区(AgNOR)研究工作的标准化方案[J].中国肿瘤临床,1996,23(5):377-377.
  • 4Moch H Kononen T K allionemi OP et al Tissue microarrays what will they bring to lolecular abnd abatuomic pathology ?Adv Anat Patol 2001,8:14-20
  • 5Ekins R,Chu FW. Microarrays: their origins and applications. Trends Biotechnol, 1999, 17, 217-218.
  • 6Wooster R. Cancer classification with DNA microarrays is less more? Trends Genet, 2000, 16:327-329.
  • 7Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res,2000,60:6617-6622.
  • 8Richter J, Wagner U, Kononen J. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol, 2000,157:787-794.
  • 9Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. CancerRes, 2000,60:5340-5344.
  • 10Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res,1999, 59:803-806.

共引文献100

同被引文献36

  • 1王英,邓碧萍,马龙华,许洋,张自森,刘芳,毛友生,张金生,张德超,赵晓航.食管鳞癌血清WCX2蛋白芯片诊断模型的研究[J].中华检验医学杂志,2004,27(10):634-637. 被引量:24
  • 2俸瑞发,邵志敏,宫晓洁.乳腺导管原位癌的诊断和治疗——附371例报道[J].肿瘤防治杂志,2005,12(8):621-622. 被引量:10
  • 3Dalton R, Abbott A. Can researchers find recipe for proteins and chips[J]. Nature, 1999, 402(6763): 718.
  • 4Lueking A, Horn M, Eickhoff H, et al. Protein microarrays for gene expression and antibody screening [ J ]. Anal Biochem, 1999, 270: 103.
  • 5Adam B L, Qu Y, Davis J W, et al, Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperlasia and healthy men[J]. Cancer Res, 2002, 62: 3609.
  • 6Petricoin E F, Ardekani A M, Hitt B A, et al. Use of proteomic patterns in serum to identify ovarian cancer [ J ].Lancet, 2002, 359: 572.
  • 7Kononen J, Bubendorf L, Kallioniemi A. Tissue mieroarray for high throughput molecular profiling of tumor specimens[J]. Nat Med, 1998, 4(7): 844.
  • 8Moeh H, Kononen T, Kallioniemi O P, et al. Tissue microarrays: what will they hfing to molecular and anatomic pathology[J]. Adv Anat Pathol, 2001, 8(1): 14.
  • 9Cheng S B, Skinnner C D, Taylor J, et al. Development of a multichannel microfludic analysis system employing affinity capillary electrophoresis for immunoassay [J]. Anal Chem,2001, 73(7): 1472.
  • 10Dodge A, Fluri K, Verpoorte E, et al. Electrokinetically driven microfluidic chips with surface-modified chambers for heterogeneous immunoassays [J ]. Anal Chem, 2001, 73(14) : 3400.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部